Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
Read the full interview with Patrik Eschricht at biostock.se:
https://www.biostock.se/2024/08/phis-ceo-comments-on-the-approved-us-listing/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/